Antibody prevalence to mumps in children and adolescents at two years of the introduction of the MMR vaccine

Abstract

Objective. To assess the prevalence of mumps antibodies in children and adolescents of Mexico, two years after the introduction of the mumps-containing vaccine MMR. Ma­terials and methods. Evaluation of IgG antibodies with a commercial kit of indirect ELISA. Results. 2 111 children (1-9 years) and 2 484 adolescents (10-19 years) were studied. The overall antibody seroprevalence was 70.6% (95% CI 69.3- 71.9), being higher in adolescents (83.0%, 95%CI 81.5-84.5) than in children (56.0%, 95%CI: 53.9-58.11) (OR 3.83, 95%CI 3.34-4.39, p=0.0000000). Children 1 to 2 and 6 to 9 years who were part of the target group of mumps vaccination since 1998, they had higher seroprevalence than the group of 3 to 5 years unvaccinated. Conclusions. Seropositivity in children aged 1 to 2 and 6 to 9 years was probably at­tributable to vaccination during 1998-2000 and in other age groups to natural exposure related to time elapsed in each birth cohort until the study recruitment.

Keywords

• parotiditis
• seroprevalencia
• vacunación
• niños
• adolescentes